



Amsterdam, 23 April 2026  
EMADOC-1700519818-3042604  
PIP compliance  
EMA/X/0000296763

## Statement indicating compliance with the agreed completed paediatric investigation plan

Medicinal product	
Skyrizi	
risankizumab	
Pharmaceutical form(s):	See Annex A of the CHMP Opinion
Strength(s):	See Annex A
Route(s) of administration:	See Annex A
Packaging and package size(s):	See Annex A
Number(s) in the Community Register of Medicinal Products:	See Annex A

Marketing Authorisation Holder (MAH):	
Name and address of the MAH:	Abbvie Deutschland GmbH & Co. KG Knollstrasse 67061 Ludwigshafen Am Rhein Germany

Procedure	
Procedure number:	EMA/X/0000296763

Further to the compliance check performed under Article 23 of Regulation (EC) No 1901/2006, and in accordance with Article 28(3) and Article 45(3) of the said Regulation it is concluded that:

- the development of this product has complied with all measures in the agreed paediatric investigation plan P/0497/2022. All studies in the agreed paediatric investigation plan P/0497/2022 were conducted after the entry into force of that Regulation,
- the Summary of Product Characteristics reflects the results of studies conducted in compliance with this agreed paediatric investigation plan.



In accordance with Article 23a of Regulation (EC) No 1234/2008, this statement indicating compliance with the agreed completed paediatric investigation plan P/0497/2022 is included in the technical dossier.